Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
statin |
| gptkbp:approvalYear |
1991
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:C10AA03
|
| gptkbp:bioavailability |
17%
|
| gptkbp:brand |
Pravachol
|
| gptkbp:CASNumber |
81131-70-6
|
| gptkbp:chemicalFormula |
C23H36O7
|
| gptkbp:contraindication |
gptkb:liver_disease
pregnancy |
| gptkbp:developedBy |
gptkb:Japan
|
| gptkbp:discoveredBy |
Sankyo Co.
|
| gptkbp:eliminationHalfLife |
1.8 hours
|
| gptkbp:excretion |
urine
feces |
| https://www.w3.org/2000/01/rdf-schema#label |
pravastatin
|
| gptkbp:interactsWith |
gptkb:cyclosporine
gptkb:gemfibrozil gptkb:erythromycin |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
HMG-CoA reductase inhibitor
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
gptkb:X_(US)
|
| gptkbp:proteinBinding |
50%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
muscle pain liver enzyme abnormalities |
| gptkbp:usedFor |
lowering cholesterol
prevention of cardiovascular disease |
| gptkbp:bfsParent |
gptkb:CYP3A4
|
| gptkbp:bfsLayer |
5
|